Similarly, QUE.NPs extensively decreased levels of IL-18 and KIM-1 when administrated in combination with cisplatin (p < 0.001) and exhibited a better effect relative to the CIS + QUE group (p < 0.05 and p < 0.001, respectively). Here, HAVCR1 is linked to in situ carcinoma.